Last updated 8 days ago

A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

2500 patients around the world

Available in Argentina, United States

Novo Nordisk A/S

15Research sites

2500Patients around the world

This study is for people with

Obesity

Diabetes

Diabetes mellitus type 2

From 18 Years

All Gender

: Male or female (sex assigned at birth, inclusive of all gender identities).
Age 18 years or above at the time of signing the informed consent.
BMI≥ 35.0 kg/m^2.
Participants without T2D: No history of T2D and HbA1c < 6.5% (48 millimoles per mole (mmol/mol)) Participants with T2D: A history of T2D and HbA1c < 10% (< 86 mmol/mol). If a participant without a history of diabetes during the screening period receives an HbA1c result of 6.5% (48 mmol/mol) or higher, the investigator or the participant's healthcare provider must confirm the diagnosis of type 2 diabetes before the participant is randomised.

: A self-reported change in body weight > 5% within 90 days before screening, irrespective of medical records.
Use of any glucagon-like-peptide-1 receptor agonist (GLP-1 RA), including medication with GLP-1 RA activity, or amylin analogues, including medication with amylin activity, within 6 months before screening.